20:38 , Sep 21, 2018 |  BioCentury  |  Politics, Policy & Law

Filling the rebate void

HHS’s proposal to eliminate drug rebates should have the intended consequence of increasing transparency into drug pricing in the short term. But the long view is that value-based pricing or alternative co-pay agreements will do...
16:43 , Sep 21, 2018 |  BC Week In Review  |  Company News

Atomwise identifying small molecules for Pfizer

Atomwise Inc. (San Francisco, Calif.) partnered with Pfizer Inc. (NYSE:PFE) to use its AI platform to identify small molecule candidates for up to three target proteins from Pfizer. Atomwise will receive an undisclosed technology access...
16:33 , Sep 21, 2018 |  BC Week In Review  |  Financial News

Ex-Kite execs prep quick IPO for CAR T play Allogene

Cell therapy start-up Allogene Therapeutics Inc. (South San Francisco, Calif.) filed to raise up to $100 million in an IPO on NASDAQ underwritten by Goldman Sachs, J.P. Morgan, Cowen and Jefferies. Launched in April with...
16:33 , Sep 21, 2018 |  BC Week In Review  |  Financial News

Biodesy raises $20M in series C, appoints new CEO

Biodesy Inc. (South San Francisco, Calif.) raised $20 million Sept. 10 in a series C round led by new investor Alexandria Venture Investments. Existing investors 5AM Ventures, Pfizer Ventures and Roche Venture Fund also participated...
21:32 , Sep 19, 2018 |  BC Innovations  |  Translation in Brief

To eat and not to eat

A Nature Communications paper published last month by Forty Seven Inc. (NASDAQ:FTSV) co-founder Irving Weissman and colleagues at Stanford University highlights a new strategy for boosting “eat me” signals on cancer cells that could complement...
22:24 , Sep 18, 2018 |  BC Extra  |  Clinical News

Sosei, Allergan to delay trials of dementia candidate

Sosei Group Corp. (Tokyo:4565) and partner Allergan plc (NYSE:AGN) have suspended clinical development of neurodegenerative candidate HTL0018318 to investigate a toxicity signal -- a rare tumor -- found in a non-human primate treated with the...
22:58 , Sep 14, 2018 |  BioCentury  |  Regulation

Closing NICE’s Orphan gap

As the list of Orphan drugs rejected by NICE grows, industry and patient groups are pressuring the agency to make broader use of tools that currently apply only to selected ultra-Orphan therapies. These tools allow...
17:29 , Sep 14, 2018 |  BC Week In Review  |  Financial News

Neurological organoid company System1 raises $25M in series A

System1 Biosciences Inc. (San Francisco, Calif.) raised $25 million in a series A round co-led by CRV and Pfizer Ventures. Alexandria Venture Investments, Dolby Family Ventures, Longevity Fund, Riot Ventures, Kinled Holding, Wilmot Ventures, Webb...
15:19 , Sep 14, 2018 |  BC Week In Review  |  Clinical News

Bavencio, Inlyta combo meets PFS endpoint in first-line RCC

Merck KGaA (Xetra:MRK) and Pfizer Inc. (NYSE:PFE) said Bavencio avelumab plus Inlyta axitinib met the primary endpoint of improving progression-free survival (PFS) vs. Sutent sunitinib in the Phase III JAVELIN Renal 101 trial to treat...
14:34 , Sep 14, 2018 |  BC Extra  |  Financial News

Ex-Kite execs prep quick IPO for CAR T play Allogene

Cell therapy start-up Allogene Therapeutics Inc. (South San Francisco, Calif.) filed to raise up to $100 million in an IPO on NASDAQ underwritten by Goldman Sachs, J.P. Morgan, Cowen and Jefferies. Launched in April with...